<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40009598</article-id><article-id pub-id-type="pmc">PMC11864536</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0317826</article-id><article-id pub-id-type="publisher-id">PONE-D-24-41262</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Eukaryota</subject><subj-group><subject>Plants</subject><subj-group><subject>Legumes</subject><subj-group><subject>Peas</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Bioassays and Physiological Analysis</subject><subj-group><subject>Electrophysiological Techniques</subject><subj-group><subject>Cardiac Electrophysiology</subject><subj-group><subject>Electrocardiography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Pulmonary Hypertension</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular Anatomy</subject><subj-group><subject>Blood Vessels</subject><subj-group><subject>Arteries</subject><subj-group><subject>Pulmonary Arteries</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular Anatomy</subject><subj-group><subject>Blood Vessels</subject><subj-group><subject>Arteries</subject><subj-group><subject>Pulmonary Arteries</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Blood Pressure</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular Anatomy</subject><subj-group><subject>Heart</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular Anatomy</subject><subj-group><subject>Heart</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular Anatomy</subject><subj-group><subject>Heart</subject><subj-group><subject>Cardiac Ventricles</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular Anatomy</subject><subj-group><subject>Heart</subject><subj-group><subject>Cardiac Ventricles</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>The value of vector ECG in predicting residual pulmonary hypertension in CTEPH patients after pulmonary endarterectomy</article-title><alt-title alt-title-type="running-head">The value of vector ECG in predicting residual pulmonary hypertension in CTEPH patients after PEA</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4776-0587</contrib-id><name><surname>Luijten</surname><given-names>Dieuwke</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Rodenburg</surname><given-names>Tamara</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bogaard</surname><given-names>Harm-Jan</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kianzad</surname><given-names>Azar</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8868-6857</contrib-id><name><surname>Ruigrok</surname><given-names>Dieuwertje</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4490-8857</contrib-id><name><surname>Croon</surname><given-names>Philip</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Smeele</surname><given-names>Patrick</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vliegen</surname><given-names>Hubert W.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Noordegraaf</surname><given-names>Anton Vonk</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Meijboom</surname><given-names>Lilian J.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9961-0754</contrib-id><name><surname>Klok</surname><given-names>Frederikus A.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Pulmonary Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis, Amsterdam, the Netherlands</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Cardiology, Amsterdam University Medical Centers, Amsterdam, the Netherlands</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Maloney</surname><given-names>James P.</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of Colorado - Anschutz Medical Campus, UNITED STATES OF AMERICA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></fn><corresp id="cor001">* E-mail: <email>d.luijten@lumc.nl</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>2</issue><elocation-id>e0317826</elocation-id><history><date date-type="received"><day>23</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>6</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Luijten et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Luijten et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0317826.pdf">
</self-uri><abstract><sec id="sec015"><title>Introduction</title><p>Right heart catheterization (RHC) is the diagnostic standard for establishing residual pulmonary hypertension (PH) after pulmonary endarterectomy (PEA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). A potential non-invasive alternative diagnostic test could be electrocardiography (ECG)-derived ventricular gradient optimized for right ventricular pressure overload (VG-RVPO).</p></sec><sec id="sec016"><title>Methods</title><p>We studied 66 CTEPH patients who underwent PEA. A subgroup of 20 patients also had a cardiac MRI before and after PEA. The diagnostic performance of the VG-RVPO for the detection of residual PH as well as the potential to replace RHC were assessed. Different cut-off values to define a normal VG-RVPO were evaluated. Also, we evaluated the association between mean pulmonary artery pressure (mPAP) and CMR derived indexed right ventricular (RV) mass and the VG-RVPO.</p></sec><sec id="sec017"><title>Results</title><p>During follow-up, 28 patients had residual PH (42%). A decrease in VG-RVPO after PEA was associated with decrease in mPAP or indexed RV mass post PEA (r&#x02009;=&#x02009;0.55, p&#x02009;&#x0003c;&#x02009;0.05 and r&#x02009;=&#x02009;0.64, p&#x02009;&#x0003c;&#x02009;0.05, respectively). If a normal VG-RVPO would exclude residual PH, the need for RHC would be reduced with 15&#x02013;48%, but up to 36% of the CTEPH patients with residual PH would have been missed as they had a normal VG-RVPO.</p></sec><sec id="sec018"><title>Conclusion</title><p>Although there was an association between the change in VG-RPVO and changes in mPAP or indexed RV mass, our study demonstrated that VG-RPVO has limited value in excluding the presence of residual PH post-PEA as up to 36% of the CTEPH patients with residual PH would have been missed if residual PH would have been excluded based on a normal VG-RVPO.</p></sec></abstract><funding-group><funding-statement>The author(s) received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="4"/><page-count count="12"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its <xref rid="sec014" ref-type="sec">Supporting information</xref> files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its <xref rid="sec014" ref-type="sec">Supporting information</xref> files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Pulmonary endarterectomy (PEA) is the treatment of choice for patients with chronic thromboembolic pulmonary hypertension (CTEPH) [<xref rid="pone.0317826.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0317826.ref003" ref-type="bibr">3</xref>]. PEA leads to improved cardiopulmonary hemodynamics and exercise tolerance with low early mortality when performed in expert centres [<xref rid="pone.0317826.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0317826.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0317826.ref005" ref-type="bibr">5</xref>]. Nevertheless, residual pulmonary hypertension (PH) after PEA is not uncommon, and associated with worse long-term survival [<xref rid="pone.0317826.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0317826.ref007" ref-type="bibr">7</xref>]. For patients with significant residual PH after PEA, balloon pulmonary angioplasty (BPA) or PAH (pulmonary arterial hypertension)-specific medication are potential treatment options to lower symptom burden.</p><p>Right heart catheterization (RHC) is the diagnostic standard for diagnosing post-PEA residual PH. Current guidelines therefore advice to perform RHC 3&#x02013;6 months after surgery. However, a non-invasive strategy to perform post-PEA follow-up might be preferred. A potential non-invasive alternative is the ECG-derived ventricular gradient optimized for right ventricular pressure overload (VG-RVPO) [<xref rid="pone.0317826.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0317826.ref010" ref-type="bibr">10</xref>]. The VG-RVPO detects right ventricle pressure overload due to right ventricle hypertrophy and changes in action potential duration as a result from pressure variations [<xref rid="pone.0317826.ref010" ref-type="bibr">10</xref>]. In a normal heart the ventricular gradient points in a left direction, therefore a normal VG-RVPO is negative. With increase of right ventricle (RV) pressure, the VG-RVPO becomes more positive and can therefore detect RV pressure overload [<xref rid="pone.0317826.ref008" ref-type="bibr">8</xref>].</p><p>Given that the VG-RVPO generates numerical values, it can be categorized into absence or presence of signs of right ventricle pressure overload using previous derived cut-off values [<xref rid="pone.0317826.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0317826.ref014" ref-type="bibr">14</xref>]. The diagnostic value of VG-RVPO for post-PEA residual PH has not been established to date. Therefore, our aim was to evaluate the diagnostic accuracy of the ECG-derived VG-RVPO for detecting residual PH in CTEPH patients who underwent PEA. To our knowledge this is the first study to investigate the diagnostic accuracy of vector ECG in detecting residual PH in CTEPH patients who underwent PEA.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>Study design and patients</title><p>This was a post-hoc analysis of the VUmc observational CTEPH follow-up cohort (Amsterdam, the Netherlands) [<xref rid="pone.0317826.ref015" ref-type="bibr">15</xref>]. All CTEPH patients undergoing PEA between July 2012 and September 2019 were eligible for inclusion. Patients were excluded if 1) they had a follow-up of &#x0003c; 6 months after PEA; 2) they did not have an available baseline ECG (i.e., ECG within one month before CTEPH diagnosis or between CTEPH diagnosis and PEA); or 3) they did not have a follow-up ECG (i.e., ECG 6-21 months after PEA). Of the included patients deidentified data from the patient chart was saved in a database. Patients were diagnosed with CTEPH according to the at inclusion applicable guideline definition (mPAP &#x02265;&#x02009;25 mmHg) [<xref rid="pone.0317826.ref016" ref-type="bibr">16</xref>]. Per clinical protocol, ECG and cardiac MRI (CMR) was routinely performed before and 6 months after PEA. Residual PH was defined as mPAP &#x02265;&#x02009;25 mmHg measured with RHC following at the inclusion applicable guideline definitions for pulmonary hypertension. The study did not fall within the scope of the Medical Research Involving Human Subjects Act, because an analysis was performed based on available clinical data obtained for clinical purposes and therefore no informed consent was obtained. This was confirmed by the Medical Ethics Review Committee of the VU University Medical Center (2017.313).</p></sec><sec id="sec004"><title>Objectives</title><p>The primary objective of this study was to investigate the diagnostic accuracy of the (&#x00394; or follow-up) VG-RVPO to detect residual PH in CTEPH patient who underwent PEA, and its efficacy and safety for making management decisions. For efficacy we evaluated the percentage of patients in whom residual PH could not have been ruled out with the VG-RVPO, i.e., the number of patients who would have had an RHC indication. For safety we evaluated the percentage of patients in whom residual PH would have been missed if residual PH would have been ruled out based on a normal VG-RVPO.</p><p>Secondary objectives were (1) to investigate the optimal cut-off value of the (&#x00394; or follow-up) VG-RVPO for the detection of residual PH and the subsequent diagnostic accuracy, efficacy and safety of this cut-off value, (2) to evaluate the correlation between VG-RVPO and the mean pulmonary artery pressure (mPAP) as measured by right heart catheterization (RHC), (3) to evaluate the correlation between VG-RVPO and right ventricular (RV) hypertrophy as measured by indexed RV mass on CMR and (4) to evaluate the diagnostic accuracy of the VG-RVPO in patients with normal versus abnormal indexed RV mass on CMR.</p></sec><sec id="sec005"><title>Procedures</title><p>RHC was performed as described previously [<xref rid="pone.0317826.ref017" ref-type="bibr">17</xref>]. ECGs were standard 10-s 12 lead ECGs recorded in supine position (25&#x02009;mm/s). To determine the ECG variables, the dedicated Leiden ECG analysis and decomposition software program (LEADS) was performed by an independent investigator blinded to patient characteristics and outcomes [<xref rid="pone.0317826.ref018" ref-type="bibr">18</xref>]. The LEADS software computes multiple vector-cardiogram (VCG) values including the ventricular gradient (VG). The VG is defined as the 3D integral of the heart vector over the QT interval and is an indicator for how the action potential morphology is distributed in the heart [<xref rid="pone.0317826.ref019" ref-type="bibr">19</xref>]. For the detection of right ventricular pressure overload (RVPO) previous research has shown that the projection in the 155 &#x000b0; azimuth and 27 &#x000b0; elevation direction is the most optimal, since this projection is directed over the right ventricle [<xref rid="pone.0317826.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0317826.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0317826.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0317826.ref013" ref-type="bibr">13</xref>]. This projection is called the VG-RVPO (ventricular gradient &#x02013; optimized for right ventricular pressure overload). Since in a normal heart the VG points in a left direction, a normal VG-RVPO is negative and with increase of right ventricular pressure the VG-RVPO becomes more positive (<bold><xref rid="pone.0317826.g001" ref-type="fig">Fig 1</xref></bold>). The VG-RVPO cut-off point for the detection of pulmonary hypertension derived from previous studies is &#x0003c;&#x02009;&#x02212;13 mV ms; meaning that a VG-RVPO &#x0003c;&#x02009;&#x02212;13 mV &#x00387; ms was considered normal (no residual PH) and a VG-RVPO of &#x02265;&#x02009; &#x02212;13 mV &#x00387; ms was considered abnormal (possible residual PH) although different cut-off points have been evaluated in this study [<xref rid="pone.0317826.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0317826.ref014" ref-type="bibr">14</xref>]. Baseline VG-RVPO was derived from the last ECG performed before PEA, follow-up VG-RVPO was derived from the ECG performed approximately 6 months after PEA. &#x00394; VG-RVPO was calculated as follows: follow-up VG-RVPO - baseline VG-RVPO.</p><fig position="float" id="pone.0317826.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0317826.g001</object-id><label>Fig 1</label><caption><title>Change in cardiac vectors from the normal physiologic situation to respectively early stage and chronic PH.</title><p>Reprinted from Couperus et al. with permission [<xref rid="pone.0317826.ref013" ref-type="bibr">13</xref>]. Pulmonary arterial hypertension PAH.</p></caption><graphic xlink:href="pone.0317826.g001" position="float"/></fig><p>CMR were performed on a 1.5 T Sonata or 1.5 T Avanto MRI scanner (Siemens Healthcare, Erlangen, Germany). A short-axis stack was performed at breath-hold per slice, with a slice thickness and interslice gap of 5&#x02009;mm. RV volume and mass were determined by manually drawing endocardial and epicardial contours at end diastole and end systole using commercially available software (QMass, Medis, Leiden, the Netherlands and Circle CVI42). RV mass was subsequently indexed to body surface area [<xref rid="pone.0317826.ref020" ref-type="bibr">20</xref>]. As healthy controls have an indexed RV mass of 22 &#x000b1;&#x02009;6&#x02009;g/m<sup>2</sup> we defined an abnormal indexed RV mass as &#x0003e; 33.76&#x02009;g/m<sup>2</sup> which is the upper limit of the 95% CI in healthy controls [<xref rid="pone.0317826.ref020" ref-type="bibr">20</xref>].</p></sec><sec id="sec006"><title>Statistical analysis</title><p>Normally distributed continuous data were described as a mean (&#x000b1;standard deviation [SD]). Abnormally distributed continuous data were described as a median (interquartile range [IQR]) and compared using a Mann-Whitney-U test. Categorical variables were described as numbers (percentage).</p><p>For the analysis of diagnostic accuracy of the VG-RVPO for post-PEA residual PH, sensitivity and specificity of the VG-RVPO (according to the predefined cut-off of &#x02265;&#x02009; &#x02212;13 mV&#x00387;ms) with corresponding confidence interval (95%CI) were calculated. Moreover, ROC curves were plotted, and the area under the curve (AUC) with corresponding 95%CI was determined.</p><p>We subsequently calculated the optimal cut-off points for VG-RVPO after PEA and for &#x00394;VG-RVPO by selecting cut-off values to define abnormality according to the highest negative predictive value. For these newly selected cut-off point, we also calculated the diagnostic accuracy as described above.</p><p>To evaluate the correlation between the VG-RVPO and mPAP and VG-RVPO and indexed RV mass, scatter plots were drawn and a Pearson correlation coefficient was calculated to quantify the strength of the using linear regression analysis.</p><p>Also we stratified all diagnostic accuracy outcomes according to normal or abnormal RV mass. Patients with bad quality CMR or those with more than 90 days between the CMR and ECG were excluded from this sub-analysis (<xref rid="pone.0317826.g002" ref-type="fig">Fig 2</xref>).</p><fig position="float" id="pone.0317826.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0317826.g002</object-id><label>Fig 2</label><caption><title>Study flow chart.</title><p>Abbreviations: CMR, cardiac magnetic resonance imaging; ECG, electrocardiogram; LTX, lung transplantation; PEA, pulmonary endarterectomy; RHC, right heart catheterization. *&#x02009; 11 patients with no CMR post PEA.</p></caption><graphic xlink:href="pone.0317826.g002" position="float"/></fig><p>We performed two sensitivity analyses: 1) residual PH defined according to the 2022 pulmonary hypertension guidelines from European Society of Cardiology (ESC); pulmonary artery pressure &#x0003e;&#x02009; 20 mmHg, pulmonary artery wedge pressure &#x0003c;&#x02009;15 mmHg and a pulmonary vascular resistance &#x0003e;&#x02009;160 dynes<sup>.</sup>s<sup>.</sup>cm<sup>&#x02212;5</sup>, and 2) excluding all patients where follow-up ECG was performed &#x0003e;&#x02009; 90 days after follow-up RHC.</p><p>All analyses were performed using R, version 4.3.1 (R Foundation for Statistical Computing; <ext-link xlink:href="https://www.R-project.org" ext-link-type="uri">www.R-project.org</ext-link>).</p></sec></sec><sec sec-type="results" id="sec007"><title>Results</title><sec id="sec008"><title>Patients</title><p>Sixty-six CTEPH patients who underwent PEA and survived a minimum of 6 months were studied (<bold><xref rid="pone.0317826.g002" ref-type="fig">Fig 2</xref></bold>). Mean age was 57 years and 56% was male (<bold><xref rid="pone.0317826.t001" ref-type="table">Table 1</xref></bold>); 86% had a history of acute pulmonary embolism and 35% of deep vein thrombosis. Before PEA, most patients had a New York Heart Association (NYHA) score of II and 37% used PH-specific medication. Pre-PEA RHC showed a mean mPAP of 42.5 mmHg (interquartile range [IQR]: 35&#x02013;50) and a mean PVR of 600 dynes<sup>.</sup>s<sup>.</sup>cm<sup>&#x02212;5</sup> (IQR 376-748). During follow-up, 28 patients were found to have residual PH (42%) with a mean mPAP of 31.0 mmHg and PVR of 303 dynes<sup>.</sup>s<sup>.</sup>cm<sup>&#x02212;5</sup> and 38 patients were found to have no residual PH with a mean mPAP of 19.2 mmHg and PVR of 176 dynes<sup>.</sup>s<sup>.</sup>cm<sup>&#x02212;5</sup>. When using the new criteria to define pulmonary hypertension based on the 2022 ESC guideline 30 patients were found to have residual PH (46%) with a mean mPAP of 28.2 mmHg and PVR of 295 dynes<sup>.</sup>s<sup>.</sup>cm<sup>&#x02212;5</sup> and 35 (54%) patients were found to have no residual PH with a mean mPAP of 20.9 mmHg and PVR of 136 dynes<sup>.</sup>s<sup>.</sup>cm<sup>&#x02212;5</sup>.</p><table-wrap position="float" id="pone.0317826.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0317826.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics.</title></caption><alternatives><graphic xlink:href="pone.0317826.t001" id="pone.0317826.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Overall (n&#x02009;=&#x02009;66)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age at PEA [years], mean (SD)</td><td align="left" rowspan="1" colspan="1">57.3 (14.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex, n (%)</td><td align="left" rowspan="1" colspan="1">37 (56.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI [kg&#x000b7;m&#x02009;&#x02212;&#x02009;2], mean (SD)</td><td align="left" rowspan="1" colspan="1">27.0 (5.9)</td></tr><tr><td align="left" colspan="2" rowspan="1">NYHA class, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;I</td><td align="left" rowspan="1" colspan="1">1 (1.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;II</td><td align="left" rowspan="1" colspan="1">24 (38.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;III</td><td align="left" rowspan="1" colspan="1">32 (50.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;IV</td><td align="left" rowspan="1" colspan="1">6 (9.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Use of PH-specific medication before PEA, n (%)</td><td align="left" rowspan="1" colspan="1">24 (36.9)</td></tr><tr><td align="left" colspan="2" rowspan="1">Comorbidities, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Acute PE</td><td align="left" rowspan="1" colspan="1">55 (85.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;DVT</td><td align="left" rowspan="1" colspan="1">20 (34.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;History of a malignancy</td><td align="left" rowspan="1" colspan="1">3 (4.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;History of a haematological disease</td><td align="left" rowspan="1" colspan="1">2 (3.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">5 (7.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Obstructive lung disease</td><td align="left" rowspan="1" colspan="1">8 (12.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Hypertension</td><td align="left" rowspan="1" colspan="1">22 (33.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Splenectomy</td><td align="left" rowspan="1" colspan="1">1 (1.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Coronary artery disease</td><td align="left" rowspan="1" colspan="1">2 (3.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Thyroid disease</td><td align="left" rowspan="1" colspan="1">5 (7.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Months between PEA to follow-up ECG/RHC, median (IQR)</td><td align="left" rowspan="1" colspan="1">6.93 (6.46&#x02013;8.23)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Mean mPAP pre PEA [mmHg], mean(SD)</td><td align="left" rowspan="1" colspan="1">42.5 (10.2)*</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Mean PVR pre-PEA [dynes<sup>.</sup>s<sup>.</sup>cm<sup>&#x02212;5</sup>], mean (SD)</td><td align="left" rowspan="1" colspan="1">600.7 (299.5)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>*patients without residual PH during follow-up had a mPAP pre PEA of 41.95 mmHg (SD 10.69), which was 43.18 mmHg (9.77) for patients with residual PH during follow-up. Abbreviations: BMI, body mass index; DVT, deep vein thrombosis; ECG, electrocardiogram; IQR, interquartile range; mPAP, mean pulmonary artery pressure; NYHA, New York Heart Association; PE, pulmonary embolism; PEA, pulmonary endarterectomy; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RHC, right heart catheterization; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec009"><title>Diagnostic accuracy of VG-RVPO</title><p>If residual PH would have been considered ruled out based on a normal follow-up VG-RVPO of &#x0003c;&#x02009;&#x02212;13 mV&#x000b7;ms, specificity&#x000a0;and sensitivity for detecting residual PH would have been 50% and 64% respectively. RHC would have been indicated in 37 patients (56%), but residual PH would have been missed in 10 out of 28 patients (35.7%; <bold><xref rid="pone.0317826.t002" ref-type="table">Table 2</xref></bold>), with a negative predictive value of 65.6%.</p><table-wrap position="float" id="pone.0317826.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0317826.t002</object-id><label>Table 2</label><caption><title>Diagnostic accuracy of specific cut-off values.</title></caption><alternatives><graphic xlink:href="pone.0317826.t002" id="pone.0317826.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1"/><th align="left" rowspan="1" colspan="1">Patients without residual PH after PEA (n&#x02009;= 38)</th><th align="left" rowspan="1" colspan="1">Patients with residual PH after PEA (n&#x02009;=&#x02009;28)</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Abnormal follow-up VG-RVPO of &#x02265;&#x02009;&#x02212;13 mV&#x000b7;ms (previously defined cut-off value)</td><td align="left" rowspan="1" colspan="1">VG-RVPO normal, n (%)</td><td align="left" rowspan="1" colspan="1">19 (50)</td><td align="left" rowspan="1" colspan="1">10 (35.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">VG-RVPO abnormal, n (%)</td><td align="left" rowspan="1" colspan="1">19 (50)</td><td align="left" rowspan="1" colspan="1">18 (64.3)</td></tr><tr><td align="left" rowspan="2" colspan="1">Abnormal follow-up VG-RVPO of &#x02265;&#x02009;&#x02212;14.7 mV&#x000b7;ms</td><td align="left" rowspan="1" colspan="1">VG-RVPO normal, n (%)</td><td align="left" rowspan="1" colspan="1">18 (47.3)</td><td align="left" rowspan="1" colspan="1">9 (32.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">VG-RVPO abnormal, n (%)</td><td align="left" rowspan="1" colspan="1">20 (52.6)</td><td align="left" rowspan="1" colspan="1">19 (67.9)</td></tr><tr><td align="left" rowspan="2" colspan="1">Abnormal &#x00394; VG-RVPO of &#x02265;&#x02009;&#x02212;24.9 mV&#x000b7;ms</td><td align="left" rowspan="1" colspan="1">VG-RVPO normal, n (%)</td><td align="left" rowspan="1" colspan="1">8 (21.1)</td><td align="left" rowspan="1" colspan="1">2 (7.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">VG-RVPO abnormal, n (%)</td><td align="left" rowspan="1" colspan="1">30 (79.0)</td><td align="left" rowspan="1" colspan="1">26 (92.9)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Abbreviations: PEA, pulmonary endarterectomy; PH, pulmonary hypertension; SD, standard deviation; VG-RVPO, ventricular gradient optimized for right ventricular pressure overload.</p></fn></table-wrap-foot></table-wrap><p>Based on the highest negative predictive value, the best cut-off value for a normal follow-up VG-RVPO would be &#x0003c;&#x02009;&#x02212;14.7 mV&#x000b7;ms (negative predictive value of 66.7%), and the best cut-off a normal &#x00394;VG-RVPO would have been &#x0003c;&#x02009;&#x02212;24.9 mV&#x000b7;ms (negative predictive value of 80%). For the newly defined cut-off for follow-up VG-RVPO, the specificity&#x000a0;would have been 47.3% and sensitivity&#x000a0;67.9%. RHC would have been indicated in 39 patients (59%), but residual PH would have been missed in 9 patients (32.1%). For the newly defined cut-off for &#x00394;VG-RVPO, the specificity&#x000a0;would have been 21.1% and sensitivity&#x000a0;92.9%. RHC would have been indicated in 56 patients (84%), but residual PH would have been missed in 2 patients (7.1%).</p><p>The overall predictive accuracy of follow-up RVPO and &#x00394; VG-RVPO for detection of CTEPH was moderate to poor, with a AUCs of the ROC ranging from 0.546 to 0.626 (<bold><xref rid="pone.0317826.t003" ref-type="table">Table 3</xref></bold>).</p><table-wrap position="float" id="pone.0317826.t003"><object-id pub-id-type="doi">10.1371/journal.pone.0317826.t003</object-id><label>Table 3</label><caption><title>AUC ROC curve.</title></caption><alternatives><graphic xlink:href="pone.0317826.t003" id="pone.0317826.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">AUC (95%CI</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">follow-up VG-RPVO</td><td align="left" rowspan="1" colspan="1">0.546 (0.396&#x02013;0.697)</td></tr><tr><td align="left" rowspan="1" colspan="1">follow-up VG-RVPO &#x02265;&#x02009;&#x02212;13 mV&#x000b7;ms</td><td align="left" rowspan="1" colspan="1">0.571 (0.45&#x02013;0.692)</td></tr><tr><td align="left" rowspan="1" colspan="1">follow-up VG-RVPO &#x02265;&#x02009;&#x02212;14.7 mV&#x000b7;ms</td><td align="left" rowspan="1" colspan="1">0.576 (0.457&#x02013;0.695)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x00394; VG-RVPO</td><td align="left" rowspan="1" colspan="1">0.626 (0.488&#x02013;0.764)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x00394; VG-RVPO &#x02265;&#x02009;&#x02212;24.9 mV&#x000b7;ms</td><td align="left" rowspan="1" colspan="1">0.570 (0.488&#x02013;0.695)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>Abbreviations: AUC, area under the curve; VG-RVPO, ventricular gradient optimized for right ventricular pressure overload</p></fn></table-wrap-foot></table-wrap><p>When evaluating diagnostic accuracy of the &#x00394;VG-RVPO to detect residual PH for patients with normal vs abnormal indexed RV mass, using the VG-RVPO only in patients with a normal indexed RV mass, would not have improved the performance. Specificity&#x000a0;would have been 36&#x02013;55% and sensitivity&#x000a0;57&#x02013;100(<xref rid="pone.0317826.s002" ref-type="supplementary-material">S1 Table</xref>, <xref rid="pone.0317826.s001" ref-type="supplementary-material">S1 Fig</xref>). Only when using the cut-off for &#x00394; VG-RVPO of &#x0003c;&#x02009;&#x02212;24.9 mV&#x000b7;ms there would have been an indication to perform RHC in 78% of the patients with a normal indexed RV mass and none of the residual PH patients with a normal indexed RV mass would have been missed. However, as the CMR sub analysis could only be performed in 20 patients and the indexed RV mass post-PEA was abnormal in only 2 patients, power was very low and these results are highly uncertain.</p></sec><sec id="sec010"><title>Sensitivity analyses for the diagnostic accuracy of VG-RVPO</title><p>When using the new criteria to define pulmonary hypertension based on the 2022 ESC guideline, we saw similar results for the mean VG-RVPO measurement in patients with/without residual PH (<xref rid="pone.0317826.s003" ref-type="supplementary-material">S2 Table</xref>). For the diagnostic performance of the VG-RVPO using the different cut-off values, specificityranged between 20&#x02013;51% and sensitivity&#x000a0;between 67&#x02013;93%. Also, the need for RHC was minimized to 57&#x02013;86%, but residual PH would have been missed in 7&#x02013;33% of the patients with residual PH (<xref rid="pone.0317826.s004" ref-type="supplementary-material">S3 Table</xref>). Overall predictive accuracy was moderate to poor (AUC ROC ranged 0.561&#x02013;0.774; <xref rid="pone.0317826.s005" ref-type="supplementary-material"><bold>S4 Table</bold></xref>).</p><p>When excluding the 10 patients with an ECG &#x0003e;&#x02009;90 days after follow-up RHC, mean VG-RVPO and diagnostic accuracy showed similar results as the main analysis (<xref rid="pone.0317826.s006" ref-type="supplementary-material">S5</xref>&#x02013; <xref rid="pone.0317826.s008" ref-type="supplementary-material">S7 Tables</xref>).</p></sec><sec id="sec011"><title>VG-RVPO measurements before and after PEA</title><p>At baseline, mean VG-RVPO was &#x02212;5.14 mV&#x000b7;ms. Post-PEA, this was &#x02212;11.2 mV&#x000b7;ms (<xref rid="pone.0317826.t004" ref-type="table">Table 4</xref>). There was no clear difference in post-PEA VG-RVPO between patients with and without residual PH (&#x02212;10.0 vs &#x02212;12.1 mV&#x000b7;ms, respectively; mean difference 2.07, 95% CI &#x02212;5.36 to 9.49). Overall, &#x00394; VG-RVPO was &#x02212;6.07 mV&#x000b7;ms, indicating a more negative VG-RVPO over time (i.e., more &#x02018;normal&#x02019;). Patients with residual PH had a numerical lower &#x00394; VG-RVPO compared to patients without residual PH (&#x02212;2.36 vs &#x02212;8.81 mV&#x000b7;ms, respectively; mean difference 6.46 mV&#x000b7;ms, 95% CI &#x02212;2.28 to 15.2)</p><table-wrap position="float" id="pone.0317826.t004"><object-id pub-id-type="doi">10.1371/journal.pone.0317826.t004</object-id><label>Table 4</label><caption><title>VG-RVPO measurements.</title></caption><alternatives><graphic xlink:href="pone.0317826.t004" id="pone.0317826.t004g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">All patients (n&#x02009;=&#x02009;66)</th><th align="left" rowspan="1" colspan="1">Patients without residual PH after PEA (n&#x02009;=&#x02009;38)</th><th align="left" rowspan="1" colspan="1">Patients with residual PH after PEA (n&#x02009;=&#x02009;38)</th><th align="left" rowspan="1" colspan="1">Mean difference (95%CI)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">VG-RVPO at baseline (mV&#x000b7;ms), mean +- SD</td><td align="left" rowspan="1" colspan="1">&#x02212;5.14 (18.2)</td><td align="left" rowspan="1" colspan="1">&#x02212;3.28 (18.5)</td><td align="left" rowspan="1" colspan="1">&#x02212;7.67 (17.8)</td><td align="left" rowspan="1" colspan="1">&#x02212;4.39 (95% CI &#x02212;13.4&#x02013;4.62)</td></tr><tr><td align="left" rowspan="1" colspan="1">VG-RVPO during follow-up (mV&#x000b7;ms), mean +- SD</td><td align="left" rowspan="1" colspan="1">&#x02212;11.2 (13.6)</td><td align="left" rowspan="1" colspan="1">&#x02212;12.09 (9.55)</td><td align="left" rowspan="1" colspan="1">&#x02212;10.0 (17.9)</td><td align="left" rowspan="1" colspan="1">2.07 (95% CI &#x02212;5.36&#x02013;9.49)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x00394; VG-RVPO (between baseline and during follow up) (mV&#x000b7;ms), mean +- SD</td><td align="left" rowspan="1" colspan="1">&#x02212;6.07 (17.8)</td><td align="left" rowspan="1" colspan="1">&#x02212;8.81 (17.9)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.36 (17.3)</td><td align="left" rowspan="1" colspan="1">6.46 (95% CI &#x02212;2.28&#x02013;15.2)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>Abbreviations: PEA, pulmonary endarterectomy; PH, pulmonary hypertension; SD, standard deviation; VG-RVPO, ventricular gradient optimized for right ventricular pressure overload.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec012"><title>Association VG-RVPO with mPAP and indexed RV mass</title><p><xref rid="pone.0317826.g003" ref-type="fig">Fig 3a</xref> depicts the association between the VG-RVPO and the mPAP measured at RHC. Before PEA, a higher mPAP is correlated with a higher VG-RVPO (r&#x02009;=&#x02009;0.49, p&#x02009;&#x0003c;&#x02009;0.05). After PEA this correlation seems to dilute, as the correlation coefficient (r) is only 0.15 (p&#x02009;=&#x02009;0.24). However, when looking at &#x00394; VG-RVPO and mPAP, a positive correlation was identified (r&#x02009;=&#x02009;0.55, p&#x02009;&#x0003c;&#x02009;0.05). <xref rid="pone.0317826.g003" ref-type="fig">Fig 3b</xref> depicts the correlation between VG-RVPO and indexed RV mass. There seems to be a positive correlation between VG-RVPO and indexed RV mass before PEA (r&#x02009;=&#x02009;0.12, p&#x02009;=&#x02009;0.63), after PEA (r&#x02009;=&#x02009;0.18, p&#x02009;=&#x02009;0.45), and over time (&#x00394;; r&#x02009;=&#x02009;0.64, p&#x02009;&#x0003c;&#x02009;0.05).</p><fig position="float" id="pone.0317826.g003"><object-id pub-id-type="doi">10.1371/journal.pone.0317826.g003</object-id><label>Fig 3</label><caption><title>Relationship between VG-RVPO and mPAPor indexed RV mass.</title><p>Abbreviations: CMR, cardiac magnetic resonance; mPAP, mean pulmonary artery pressure; PEA, pulmonary endarterectomy; RV, right ventricle; VG-RVPO, ventricular gradient optimized for right ventricular pressure overload.</p></caption><graphic xlink:href="pone.0317826.g003" position="float"/></fig></sec></sec><sec sec-type="conclusions" id="sec013"><title>Discussion</title><p>The main goal of this study was to evaluate the diagnostic accuracy of the VG-RVPO for detecting residual PH in CTEPH patients post PEA. Unfortunately, although the pre-PEA and &#x00394; VG-RVPO significantly correlated with mPAP and indexed RV mass, the use of the VG-RVPO in detecting residual PH was limited as 36% of the CTEPH patients with residual PH had a normal VG-RVPO and 7% had a clear improvement of VG-RVPO over time. This suggests that relying solely on VG-RVPO for the detection of residual PH would result in overlooking a substantial portion of affected individuals.</p><p>Chronically increased pulmonary artery pressure resulting in RV pressure overload includes changes in action potential duration that can be detected using vector ECG. The VG-RVPO, a vector gradient optimized to detect RV pressure overload, operates on this principle. Given that VG-RVPO measurement is a non-invasive tool, we hypothesized its potential utility in detecting persistent increased pulmonary artery pressure (i.e., residual PH) in CTEPH patients following PEA. Indeed before PEA there was correlation between increased mPAP or indexed RV mass and the VG-RVPO. However, our study found that VG-RVPO did not perform adequately in excluding the presence of residual PH after PEA, likely due to remodeling of the heart after PEA.</p><p>One of the factors contributing to the underperformance of the VG-RVPO related to remodeling of the heart after PEA might be persistent RV hypertrophy. Following PEA there is a reduction in RV mass, although it does not fully normalize compared to healthy controls [<xref rid="pone.0317826.ref020" ref-type="bibr">20</xref>]. In some CTEPH patients, RV hypertrophy may persist despite normalization of pulmonary artery pressure post-PEA, leading to an abnormal VG-RVPO. This could diminish the discriminative ability of the VG-RVPO in detecting residual PH. However, even in patients with a normalized RV mass, the diagnostic accuracy of the VG-RVPO for detecting residual PH was poor. Although it should be noted that the power of this analysis was severely limited due to the availability of CMR data in only 20 patients. Therefore, definitive conclusions regarding this sub-analysis cannot be drawn.</p><p>Given that the VG-RVPO was designed to detect electrophysiological changes in action potential duration rather than sole RV hypertrophy [<xref rid="pone.0317826.ref008" ref-type="bibr">8</xref>], it&#x02019;s crucial to consider other factors related to the remodeling of the heart after PEA that may impact its performance in discriminating residual PH. One such factor post-PEA could be the persistent abnormality in the composition of the heart. Despite the decrease in RV mass post-PEA, Braams and colleagues have demonstrated that the composition of the heart after PEA remains abnormal [<xref rid="pone.0317826.ref020" ref-type="bibr">20</xref>]. The persistent altered composition might lead to heterogeneity in action potential duration, thus influencing the ability of the VG-RVPO to detect increased pulmonary artery pressure. Therefore, beyond RV hypertrophy, the ongoing abnormality in the heart&#x02019;s composition post-PEA could contribute to the suboptimal performance of VG-RVPO in this context.</p><p>Overall, the VG-RVPO seems to effectively detect increased pulmonary artery pressure before PEA which aligns with a previous study demonstrating that the VG-RVPO significantly correlated with increased mPAP in patients with suspected PH and effectively identifies PH in systemic sclerosis patients [<xref rid="pone.0317826.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0317826.ref009" ref-type="bibr">9</xref>]. However, due to heart remodeling post-PEA, the additional value of the VG-RVPO in identifying residual pulmonary hypertension (PH) post-PEA is limited. A previous study also showed limited use of the VG-RVPO in the detection of CTEPH in acute PE survivors, possibly due to the diluting effect of persistent RV pressure overload in non-CTEPH acute PE survivors [<xref rid="pone.0317826.ref021" ref-type="bibr">21</xref>]. Whether the VG-RVPO could still contribute to the diagnostic of suspected PH in other patient categories remains unclear.</p><p>Our study has some limitations. First, ECG data before or after PEA was unavailable in a proportion of the CTEPH patients. While this missing data is likely random, the possibility of selection bias cannot be entirely ruled out. Second, there was a time gap between the ECGs and RHC, as it was not mandatory to conduct ECGs on the same day as the catheterization procedure. As a result in 10 patients, ECGs were conducted more than 90 days after right heart catheterization. However, we addressed this limitation by conducting a sensitivity analysis excluding these patients, which yielded similar results. Third, CMR data was only accessible in 20 patients. As a result, the sub-analysis involving CMR is underpowered, and definitive conclusions cannot be drawn. Lastly, (residual) PH was defined as mPAP&#x02009;&#x02265;&#x02009;25 mmHg measured with RHC according to the current guideline at time of inclusion of this cohort [<xref rid="pone.0317826.ref016" ref-type="bibr">16</xref>]. Therefore applicability of our findings to CTEPH patients diagnosed using the 2022 definition of PH may be debatable. To address concerns regarding the applicability of the definition of residual PH, we conducted a sensitivity analysis classifying CTEPH patients with residual PH according to the 2022 definition, yielding similar results.</p><p>In conclusion, while we observed a correlation between VG-RVPO and increased pulmonary artery pressure in CTEPH patients before PEA, this correlation appears to diminish after PEA. The remodeling of the heart after PEA such as persistent abnormality in the composition of the heart or persistent RV hypertrophy despite normalization of the pulmonary artery pressure seems to clarify why our study did not demonstrate a relevant diagnostic value of VG-RVPO for detecting PH in CTEPH patients post-PEA. These findings suggest that the utility of VG-RVPO is limited in this context, highlighting the need for further research to explore alternative approaches to improve (non-invasive) follow-up of CTEPH patients post PEA.</p></sec><sec id="sec014" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0317826.s001" position="float" content-type="local-data"><label>S1 Fig</label><caption><title>VG-RVPO and indexed RV mass pre- and post-PEA.</title><p>Dashed line presents the threshold for normal VG-RVPO or indexed RV mass. Below the black dashed line are the normal values, above abnormal. Abbreviations: PEA, pulmonary endarterectomy; RV, right ventricle; VG-RVPO, ventricular gradient optimized for right ventricular pressure overload.</p><p>(TIF)</p></caption><media xlink:href="pone.0317826.s001.tif"/></supplementary-material><supplementary-material id="pone.0317826.s002" position="float" content-type="local-data"><label>S1 Table</label><caption><title>Diagnostic accuracy of specific cut-off values, sensitivity analysis according to normal or abnormal RV mass.</title><p>Abbreviations: PEA, pulmonary endarterectomy; PH, pulmonary hypertension; RV right ventricle; SD, standard deviation; VG-RVPO, ventricular gradient optimized for right ventricular pressure overload.</p><p>(DOCX)</p></caption><media xlink:href="pone.0317826.s002.docx"/></supplementary-material><supplementary-material id="pone.0317826.s003" position="float" content-type="local-data"><label>S2 Table</label><caption><title>Overall accuracy of VG-RVPO; sensitivity analysis residual PH according to ESC 2022 PH guidelines *&#x02009; 1 patient excluded because of missing PVR data.</title><p>Abbreviations: PEA, pulmonary endarterectomy; PH, pulmonary hypertension; SD, standard deviation; VG-RVPO, ventricular gradient optimized for right ventricular pressure overload.</p><p>(DOCX)</p></caption><media xlink:href="pone.0317826.s003.docx"/></supplementary-material><supplementary-material id="pone.0317826.s004" position="float" content-type="local-data"><label>S3 Table</label><caption><title>Diagnostic accuracy of specific cut-off values; sensitivity analysis residual PH according to ESC 2022 PH guidelines.</title><p>Abbreviations: PEA, pulmonary endarterectomy; PH, pulmonary hypertension; SD, standard deviation; VG-RVPO, ventricular gradient optimized for right ventricular pressure overload.</p><p>(DOCX)</p></caption><media xlink:href="pone.0317826.s004.docx"/></supplementary-material><supplementary-material id="pone.0317826.s005" position="float" content-type="local-data"><label>S4 Table</label><caption><title>AUC ROC curve; sensitivity analysis residual PH according to ESC 2022 PH guidelines.</title><p>Abbreviations: AUC, area under the curve; VG-RVPO, ventricular gradient optimized for right ventricular pressure overload.</p><p>(DOCX)</p></caption><media xlink:href="pone.0317826.s005.docx"/></supplementary-material><supplementary-material id="pone.0317826.s006" position="float" content-type="local-data"><label>S5 Table</label><caption><title>Overall accuracy of VG-RVPO; sensitivity analysis ECG &#x0003e;&#x02009;90 days after RHC excluded.</title><p>Abbreviations: PEA, pulmonary endarterectomy; PH, pulmonary hypertension; SD, standard deviation; VG-RVPO, ventricular gradient optimized for right ventricular pressure overload.</p><p>(DOCX)</p></caption><media xlink:href="pone.0317826.s006.docx"/></supplementary-material><supplementary-material id="pone.0317826.s007" position="float" content-type="local-data"><label>S6 Table</label><caption><title>Diagnostic accuracy of specific cut-off values; sensitivity analysis ECG &#x0003e;&#x02009;90 days after RHC excluded.</title><p>Abbreviations: PEA, pulmonary endarterectomy; PH, pulmonary hypertension; SD, standard deviation; VG-RVPO, ventricular gradient optimized for right ventricular pressure overload.</p><p>(DOCX)</p></caption><media xlink:href="pone.0317826.s007.docx"/></supplementary-material><supplementary-material id="pone.0317826.s008" position="float" content-type="local-data"><label>S7 Table</label><caption><title>AUC ROC curve; sensitivity analysis ECGs &#x0003e;&#x02009;90 days after RHC excluded.</title><p>Abbreviations: AUC, area under the curve; VG-RVPO, ventricular gradient optimized for right ventricular pressure overload.</p><p>(DOCX)</p></caption><media xlink:href="pone.0317826.s008.docx"/></supplementary-material><supplementary-material id="pone.0317826.s009" position="float" content-type="local-data"><label>S1 File</label><caption><title>Data availability.</title><p>(CSV)</p></caption><media xlink:href="pone.0317826.s009.csv"/></supplementary-material></sec></body><back><ack><p>Declaration of generative AI and AI-assisted technologies in the writing process: During the preparation of this work the authors used ChatGPT to improve readability. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.</p></ack><glossary><title>Abbreviation</title><def-list><def-item><term>
&#x00394;VG-RVPO
</term><def><p>Change in Ventricular Gradient Optimized for Right Ventricular Pressure Overload</p></def></def-item><def-item><term>
ECG
</term><def><p>Electrocardiogram</p></def></def-item><def-item><term>
ESC
</term><def><p>European Society of Cardiology</p></def></def-item><def-item><term>
IQR
</term><def><p>Interquartile Range</p></def></def-item><def-item><term>
LEADS
</term><def><p>Leiden ECG Analysis and Decomposition Software</p></def></def-item><def-item><term>
mPAP
</term><def><p>Mean Pulmonary Artery Pressure</p></def></def-item><def-item><term>
MRI
</term><def><p>Magnetic Resonance Imaging</p></def></def-item><def-item><term>
NYHA
</term><def><p>New York Heart Association</p></def></def-item><def-item><term>
PAH
</term><def><p>Pulmonary Arterial Hypertension</p></def></def-item><def-item><term>
PEA
</term><def><p>Pulmonary Endarterectomy</p></def></def-item><def-item><term>
PH
</term><def><p>Pulmonary Hypertension</p></def></def-item><def-item><term>
PVR
</term><def><p>Pulmonary Vascular Resistance</p></def></def-item><def-item><term>
RHC
</term><def><p>Right Heart Catheterization</p></def></def-item><def-item><term>
RV
</term><def><p>Right Ventricle</p></def></def-item><def-item><term>
RVPO
</term><def><p>Right Ventricular Pressure Overload</p></def></def-item><def-item><term>
SD
</term><def><p>Standard Deviation</p></def></def-item><def-item><term>
VG
</term><def><p>Ventricular Gradient</p></def></def-item><def-item><term>
VG-RVPO
</term><def><p>Ventricular Gradient Optimized for Right Ventricular Pressure Overload.</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pone.0317826.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Delcroix</surname><given-names>M</given-names></name>, <name><surname>Torbicki</surname><given-names>A</given-names></name>, <name><surname>Gopalan</surname><given-names>D</given-names></name>, <name><surname>Sitbon</surname><given-names>O</given-names></name>, <name><surname>Klok</surname><given-names>FA</given-names></name>, <name><surname>Lang</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>ERS Statement on chronic thromboembolic pulmonary hypertension</article-title>. <source>Eur Respir J</source>. <year>2020</year>;<volume>57</volume>(<issue>6</issue>):<fpage>2002828</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1183/13993003.02828-2020</pub-id></mixed-citation></ref><ref id="pone.0317826.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Konstantinides</surname><given-names>SV</given-names></name>, <name><surname>Meyer</surname><given-names>G</given-names></name>, <name><surname>Becattini</surname><given-names>C</given-names></name>, <name><surname>Bueno</surname><given-names>H</given-names></name>, <name><surname>Geersing</surname><given-names>G-J</given-names></name>, <name><surname>Harjola</surname><given-names>V-P</given-names></name>, <etal>et al</etal>; <collab>The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)</collab>. <article-title>2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)</article-title>. <source>Eur Respir J</source>. <year>2019</year>;<volume>54</volume>(<issue>3</issue>):<fpage>1901647</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1183/13993003.01647-2019</pub-id>
<pub-id pub-id-type="pmid">31473594</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Gali&#x000e8;</surname><given-names>N</given-names></name>, <name><surname>Humbert</surname><given-names>M</given-names></name>, <name><surname>Vachiery</surname><given-names>J-L</given-names></name>, <name><surname>Gibbs</surname><given-names>S</given-names></name>, <name><surname>Lang</surname><given-names>I</given-names></name>, <name><surname>Torbicki</surname><given-names>A</given-names></name>, <etal>et al</etal>; <collab>ESC Scientific Document Group</collab>. <article-title>2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)</article-title>. <source>Eur Heart J</source>. <year>2015</year>;<volume>37</volume>(<issue>1</issue>):<fpage>67</fpage>&#x02013;<lpage>119</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/eurheartj/ehv317</pub-id>
<pub-id pub-id-type="pmid">26320113</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Jaff</surname><given-names>MR</given-names></name>, <name><surname>McMurtry</surname><given-names>MS</given-names></name>, <name><surname>Archer</surname><given-names>SL</given-names></name>, <name><surname>Cushman</surname><given-names>M</given-names></name>, <name><surname>Goldenberg</surname><given-names>N</given-names></name>, <name><surname>Goldhaber</surname><given-names>SZ</given-names></name>, <etal>et al</etal>; <collab>American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation</collab>. <article-title>Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>123</volume>(<issue>16</issue>):<fpage>1788</fpage>&#x02013;<lpage>830</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIR.0b013e318214914f</pub-id>
<pub-id pub-id-type="pmid">21422387</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>NH</given-names></name>, <name><surname>Delcroix</surname><given-names>M</given-names></name>, <name><surname>Jenkins</surname><given-names>DP</given-names></name>, <name><surname>Channick</surname><given-names>R</given-names></name>, <name><surname>Dartevelle</surname><given-names>P</given-names></name>, <name><surname>Jansa</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Chronic thromboembolic pulmonary hypertension</article-title>. <source>J Am Coll Cardiol</source>. <year>2013</year>;<volume>62</volume>(<issue>25 Suppl</issue>):<fpage>D92</fpage>&#x02013;<lpage>99</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jacc.2013.10.024</pub-id>
<pub-id pub-id-type="pmid">24355646</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Cannon</surname><given-names>JE</given-names></name>, <name><surname>Su</surname><given-names>L</given-names></name>, <name><surname>Kiely</surname><given-names>DG</given-names></name>, <name><surname>Page</surname><given-names>K</given-names></name>, <name><surname>Toshner</surname><given-names>M</given-names></name>, <name><surname>Swietlik</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the united kingdom national cohort</article-title>. <source>Circulation</source>. <year>2016</year>;<volume>133</volume>(<issue>18</issue>):<fpage>1761</fpage>&#x02013;<lpage>71</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.019470</pub-id>
<pub-id pub-id-type="pmid">27052413</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Quadery</surname><given-names>SR</given-names></name>, <name><surname>Swift</surname><given-names>AJ</given-names></name>, <name><surname>Billings</surname><given-names>CG</given-names></name>, <name><surname>Thompson</surname><given-names>AAR</given-names></name>, <name><surname>Elliot</surname><given-names>CA</given-names></name>, <name><surname>Hurdman</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension</article-title>. <source>Eur Respir J</source>. <year>2018</year>;<volume>52</volume>(<issue>3</issue>):<fpage>1800589</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1183/13993003.00589-2018</pub-id>
<pub-id pub-id-type="pmid">30002102</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Kamphuis</surname><given-names>VP</given-names></name>, <name><surname>Haeck</surname><given-names>MLA</given-names></name>, <name><surname>Wagner</surname><given-names>GS</given-names></name>, <name><surname>Maan</surname><given-names>AC</given-names></name>, <name><surname>Maynard</surname><given-names>C</given-names></name>, <name><surname>Delgado</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Electrocardiographic detection of right ventricular pressure overload in patients with suspected pulmonary hypertension</article-title>. <source>J Electrocardiol</source>. <year>2014</year>;<volume>47</volume>(<issue>2</issue>):<fpage>175</fpage>&#x02013;<lpage>82</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jelectrocard.2013.10.010</pub-id>
<pub-id pub-id-type="pmid">24370072</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Meijer</surname><given-names>FMM</given-names></name>, <name><surname>Kies</surname><given-names>P</given-names></name>, <name><surname>Jongbloed</surname><given-names>MRM</given-names></name>, <name><surname>van Wijngaarden</surname><given-names>SE</given-names></name>, <name><surname>Swenne</surname><given-names>CA</given-names></name>, <name><surname>Man</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>ECG derived ventricular gradient exceeds echocardiography in the early detection of pulmonary hypertension in scleroderma patients</article-title>. <source>Int J Cardiol</source>. <year>2018</year>;<volume>273</volume>:<fpage>203</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijcard.2018.07.122</pub-id>
<pub-id pub-id-type="pmid">30097334</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Henkens</surname><given-names>IR</given-names></name>, <name><surname>Mouchaers</surname><given-names>KTB</given-names></name>, <name><surname>Vonk-Noordegraaf</surname><given-names>A</given-names></name>, <name><surname>Boonstra</surname><given-names>A</given-names></name>, <name><surname>Swenne</surname><given-names>CA</given-names></name>, <name><surname>Maan</surname><given-names>AC</given-names></name>, <etal>et al</etal>. <article-title>Improved ECG detection of presence and severity of right ventricular pressure load validated with cardiac magnetic resonance imaging</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2008</year>;<volume>294</volume>(<issue>5</issue>):<fpage>H2150</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1152/ajpheart.01312.2007</pub-id>
<pub-id pub-id-type="pmid">18310513</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Meijer</surname><given-names>FMM</given-names></name>, <name><surname>Hendriks</surname><given-names>SV</given-names></name>, <name><surname>Huisman</surname><given-names>MV</given-names></name>, <name><surname>Swenne</surname><given-names>CA</given-names></name>, <name><surname>Kies</surname><given-names>P</given-names></name>, <name><surname>Jongbloed</surname><given-names>MRM</given-names></name>, <etal>et al</etal>. <article-title>The prognostic value of ECG-derived ventricular gradient in early adverse events in acute pulmonary embolism patients</article-title>. <source>Thrombosis Update</source>. <year>Update 2021</year>;<volume>2</volume>:<fpage>100033</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.tru.2021.100033</pub-id></mixed-citation></ref><ref id="pone.0317826.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Meijer</surname><given-names>FMM</given-names></name>, <name><surname>Hendriks</surname><given-names>SV</given-names></name>, <name><surname>Huisman</surname><given-names>MV</given-names></name>, <name><surname>van der Hulle</surname><given-names>T</given-names></name>, <name><surname>Swenne</surname><given-names>CA</given-names></name>, <name><surname>Kies</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Lack of diagnostic utility of the ECG-derived ventricular gradient in patients with suspected acute pulmonary embolism</article-title>. <source>J Electrocardiol</source>. <year>2020</year>;<volume>61</volume>:<fpage>141</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jelectrocard.2020.06.006</pub-id>
<pub-id pub-id-type="pmid">32619875</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Couperus</surname><given-names>LE</given-names></name>, <name><surname>Vliegen</surname><given-names>HW</given-names></name>, <name><surname>Henkens</surname><given-names>IR</given-names></name>, <name><surname>Maan</surname><given-names>AC</given-names></name>, <name><surname>Treskes</surname><given-names>RW</given-names></name>, <name><surname>de Vries</surname><given-names>JK</given-names></name>, <etal>et al</etal>. <article-title>Electrocardiographic detection of pulmonary hypertension in patients with systemic sclerosis using the ventricular gradient</article-title>. <source>J Electrocardiol</source>. <year>2016</year>;<volume>49</volume>(<issue>1</issue>):<fpage>60</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jelectrocard.2015.09.003</pub-id>
<pub-id pub-id-type="pmid">26489821</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Scherptong</surname><given-names>RWC</given-names></name>, <name><surname>Henkens</surname><given-names>IR</given-names></name>, <name><surname>Man</surname><given-names>SC</given-names></name>, <name><surname>Le Cessie</surname><given-names>S</given-names></name>, <name><surname>Vliegen</surname><given-names>HW</given-names></name>, <name><surname>Draisma</surname><given-names>HHM</given-names></name>, <etal>et al</etal>. <article-title>Normal limits of the spatial QRS-T angle and ventricular gradient in 12-lead electrocardiograms of young adults: dependence on sex and heart rate</article-title>. <source>J Electrocardiol</source>. <year>2008</year>;<volume>41</volume>(<issue>6</issue>):<fpage>648</fpage>&#x02013;<lpage>55</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jelectrocard.2008.07.006</pub-id>
<pub-id pub-id-type="pmid">18817923</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Ruigrok</surname><given-names>D</given-names></name>, <name><surname>Handoko</surname><given-names>ML</given-names></name>, <name><surname>Meijboom</surname><given-names>LJ</given-names></name>, <name><surname>Nossent</surname><given-names>EJ</given-names></name>, <name><surname>Boonstra</surname><given-names>A</given-names></name>, <name><surname>Braams</surname><given-names>NJ</given-names></name>, <etal>et al</etal>. <article-title>Noninvasive follow-up strategy after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension</article-title>. <source>ERJ Open Res</source>. <year>2022</year>;<volume>8</volume>(<issue>2</issue>):<fpage>00564</fpage>&#x02013;<lpage>2021</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1183/23120541.00564-2021</pub-id>
<pub-id pub-id-type="pmid">35586450</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Galie</surname><given-names>N</given-names></name>, <name><surname>Humbert</surname><given-names>M</given-names></name>, <name><surname>Vachiery</surname><given-names>JL</given-names></name>, <name><surname>Gibbs</surname><given-names>S</given-names></name>, <name><surname>Lang</surname><given-names>I</given-names></name>, <name><surname>Torbicki</surname><given-names>A</given-names></name>, <etal>et al</etal>; <collab>ESC Scientific Document Group</collab>. <article-title>2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)</article-title>. <source>Eur Heart J</source>. <year>2016</year>;<volume>37</volume>(<issue>1</issue>):<fpage>67</fpage>&#x02013;<lpage>119</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/eurheartj/ehv317</pub-id>
<pub-id pub-id-type="pmid">26320113</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>van de Veerdonk</surname><given-names>MC</given-names></name>, <name><surname>Kind</surname><given-names>T</given-names></name>, <name><surname>Marcus</surname><given-names>JT</given-names></name>, <name><surname>Mauritz</surname><given-names>G-J</given-names></name>, <name><surname>Heymans</surname><given-names>MW</given-names></name>, <name><surname>Bogaard</surname><given-names>H-J</given-names></name>, <etal>et al</etal>. <article-title>Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>58</volume>(<issue>24</issue>):<fpage>2511</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jacc.2011.06.068</pub-id>
<pub-id pub-id-type="pmid">22133851</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Draisma</surname><given-names>HHM</given-names></name>, <name><surname>Swenne</surname><given-names>CA</given-names></name>, <name><surname>van de Vooren</surname><given-names>H</given-names></name>, <name><surname>Maan</surname><given-names>AC</given-names></name>, <name><surname>Hooft van Huysduynen</surname><given-names>B</given-names></name>, <name><surname>van der Wall</surname><given-names>EE</given-names></name>, <etal>et al</etal>. <article-title>LEADS An interactive research oriented ECG/VCG analysis system</article-title>. <source>Comput Cardiol</source>. <year>2005</year>;<fpage>515</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1109/cic.2005.1588151</pub-id></mixed-citation></ref><ref id="pone.0317826.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Draisma</surname><given-names>HHM</given-names></name>, <name><surname>Schalij</surname><given-names>MJ</given-names></name>, <name><surname>van der Wall</surname><given-names>EE</given-names></name>, <name><surname>Swenne</surname><given-names>CA</given-names></name>. <article-title>Elucidation of the spatial ventricular gradient and its link with dispersion of repolarization</article-title>. <source>Heart Rhythm</source>. <year>2006</year>;<volume>3</volume>(<issue>9</issue>):<fpage>1092</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.hrthm.2006.05.025</pub-id>
<pub-id pub-id-type="pmid">16945809</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Braams</surname><given-names>NJ</given-names></name>, <name><surname>Kianzad</surname><given-names>A</given-names></name>, <name><surname>van Wezenbeek</surname><given-names>J</given-names></name>, <name><surname>Wessels</surname><given-names>JN</given-names></name>, <name><surname>Jansen</surname><given-names>SMA</given-names></name>, <name><surname>Andersen</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Long-Term Effects of Pulmonary Endarterectomy on Right Ventricular Stiffness and Fibrosis in Chronic Thromboembolic Pulmonary Hypertension</article-title>. <source>Circ Heart Fail</source>. <year>2023</year>;<volume>16</volume>(<issue>10</issue>):<fpage>e010336</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.122.010336</pub-id>
<pub-id pub-id-type="pmid">37675561</pub-id>
</mixed-citation></ref><ref id="pone.0317826.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Luijten</surname><given-names>D</given-names></name>, <name><surname>Meijer</surname><given-names>FMM</given-names></name>, <name><surname>Boon</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Diagnostic efficacy of ECG-derived ventricular gradient for the detection of chronic thromboembolic pulmonary hypertension in patients with acute pulmonary embolism</article-title>. <source>J Electrocardiol</source>. <year>2022</year>;<volume>74</volume>:<fpage>94</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">36057190</pub-id>
</mixed-citation></ref></ref-list></back></article>